About EndoProtech
EndoProtech is a Healthcare company based in Louisville (United States) founded in 2005. Liposome-based therapies are developed for myocardial infarction and liver disease. EndoProtech offers products and services including Liposome-based Therapies. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Stroke. Its legal entity is EndoProtech Inc. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Kriya Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
EndoProtech was established in 2005 in Louisville, United States, within the biotechnology sector. Liposome-based therapies are focused on by the company for treating myocardial infarction and alcoholic liver disease. Operations center on a portfolio of two products: EndoGuard addresses cardiac microvascular obstruction after coronary artery revascularization, while Endohepal utilizes liposomal-rolipram for alcoholic hepatitis management.
- Headquarters Louisville, United States
- SectorsHealthcare
- Website endoprotech.com
- Social LinkedIn Facebook
- Legal Name Endoprotech Inc
- Latest Funding Round$963.67K (USD), Grant
Jul 2009
- Investors
Products & Services of EndoProtech
EndoProtech offers a comprehensive portfolio of products and services, including Liposome-based Therapies.
Therapies targeting microvascular dysfunction and myocardial infarction.
Funding Insights of EndoProtech
- Total Rounds 3
- Last Round Grant — $963,666
- First Round $963,666
(May 2005)
- Investors Count 1
All 3 funding rounds of EndoProtech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in EndoProtech
EndoProtech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for EndoProtech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of EndoProtech
3 dated milestones of EndoProtech across 4 years, from founding to its latest funding, stage changes and deals.
- Founded EndoProtech is founded.
- Funding First funding round of $964K.
- Funding Latest funding round, Grant, of $964K.
Competitors of EndoProtech
EndoProtech has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Kriya Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes |
Detailed competitors of EndoProtech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as EndoProtech (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EndoProtech
EndoProtech was founded in 2005.
EndoProtech is headquartered in Louisville, United States. It is registered at Louisville, Kentucky, United States.
EndoProtech was established in 2005 in Louisville, United States, within the biotechnology sector. Liposome-based therapies are focused on by the company for treating myocardial infarction and alcoholic liver disease. Operations center on a portfolio of two products: EndoGuard addresses cardiac microvascular obstruction after coronary artery revascularization, while Endohepal utilizes liposomal-rolipram for alcoholic hepatitis management.
EndoProtech's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Kriya Therapeutics.
EndoProtech offers Liposome-based Therapies.
EndoProtech has 1 investor. Key investors include HHS.
EndoProtech operates through Endoprotech Inc.